ICA • Pharmaceutical Sector
FDA 21 CFR Part 11 means every access decision is auditable. ICA captures the requirements from day one — mapping GxP system access, clinical data governance, and manufacturing controls before a single policy is written.
Let's Talk Pharma IAM DiscoveryThe Uncomfortable Math
The Case
Pharmaceutical and life sciences organizations operate under FDA regulations that require electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records. 21 CFR Part 11 mandates that access to regulated systems is controlled, logged, and auditable. This is not a suggestion — it is a condition of approval.
Every IAM/IGA/PAM implementation in pharma must account for GxP system access, clinical trial data governance, and manufacturing system controls. The discovery phase is where these access requirements are defined across R&D, manufacturing, quality, and regulatory affairs — four functions with different access profiles and different regulatory obligations.
When that takes 8 weeks, validation timelines extend and audit readiness is delayed. FDA inspection readiness is not a switch you flip at the end of implementation. It starts with a defensible requirements document that maps access controls to 21 CFR Part 11 requirements from day one.
ICA structures this discovery in under 10 days with output that maps to the access control requirements of 21 CFR Part 11 and Annex 11. Your consulting team stops tracking down QA representatives and starts delivering a validated requirements baseline.
Regulatory Context
Every framework below touches identity and access governance requirements in pharmaceutical and life sciences. These are the mandates ICA discovery maps against.
Electronic records, electronic signatures, and access controls — the foundational regulatory requirement for controlled system access in US pharma operations.
Computerized systems validation and access management for pharmaceutical manufacturers operating in or supplying the European market.
Good practice requirements touching system access across manufacturing, laboratory, and clinical functions — each with distinct access control obligations.
Where pharma companies handle patient data in clinical trial contexts — access governance for systems storing protected health information.
Where publicly traded pharma companies face financial reporting controls — access certification and segregation of duties for financial systems.
Use Cases
GSI Partners
Deloitte, Accenture, PwC, and similar firms running IGA implementations at pharma companies use ICA to compress pre-project discovery — delivering a 21 CFR Part 11-aligned requirements baseline before the validation team starts their work.
Boutique Specialists
Life sciences IT consultancies specializing in GxP compliance use ICA to structure discovery across R&D, manufacturing, quality, and regulatory functions — capturing cross-functional access requirements that standard IGA discovery tools miss.
End Client
Pharma companies and biotech firms evaluating IGA platforms ahead of FDA audit cycles need a requirements baseline that maps directly to 21 CFR Part 11. ICA produces that baseline in under 10 days — before vendor selection begins.
If you lead an identity practice serving pharmaceutical or life sciences organizations, I would like 30 minutes to show you how ICA fits your delivery model.
Got it.
I will be in touch within 24 hours.
— Bill Leonard